<DOC>
	<DOCNO>NCT01023256</DOCNO>
	<brief_summary>GM-CSF consider key role initiation progression arthritic inflammation . The purpose study evaluate safety , preliminary efficacy , pharmacokinetics , immunogenicity multiple dos MOR103 , human antibody GM-CSF , patient active rheumatoid arthritis .</brief_summary>
	<brief_title>Safety Preliminary Efficacy MOR103 Patients With Active Rheumatoid Arthritis</brief_title>
	<detailed_description>Rheumatoid arthritis ( RA ) chronic systemic inflammatory disease affect 0.5 % 1 % adult population world wide . RA primarily affect joint characterize chronic inflammation synovial tissue , eventually lead destruction cartilage , bone ligament cause joint deformity . Pro-inflammatory cytokine , tumor necrosis factor-alpha ( TNFα ) , interleukin ( IL ) -1 , IL-6 granulocyte macrophage colony stimulate factor ( GM-CSF ) , lead activation proliferation immune cell , find increase inflamed joint . Several preclinical finding support anti-GM-CSF therapy RA .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Rheumatoid arthritis ( RA ) per revise 1987 ACR criterion Active RA : ≥3 swell 3 tender joint least 1 swollen joint hand , exclude PIP joint CRP &gt; 5.0 mg/L ( RF antiCCP seronegative ) ; CRP &gt; 2 mg/l ( RF and/or antiCCP seropositive ) DAS28 ≤ 5.1 Stable regimen concomitant RA therapy ( NSAIDs , steroid , non biological DMARDs ) . Negative PPD tuberculin skin test Previous therapy B T cell deplete agent Rituximab ( e.g . Campath ) . Prior treatment Rituximab , TNFinhibitors , biologics ( e.g . antiIL1 therapy ) systemic immunosuppressive agent allow washout period . Any history ongoing , significant recur infection Any active inflammatory disease RA Treatment systemic investigational drug within 6 month prior screen Women childbearing potential , unless receive stable dos methotrexate leflunomide Significant cardiac pulmonary disease ( include methotrexate associate lung toxicity ) Hepatic renal insufficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>GM-CSF</keyword>
	<keyword>MOR103</keyword>
</DOC>